01/06/	jc710 U	
6/00	S. PTO	

01-07100





Please type a plus sign (+) inside this box → +

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b),

Attorney Docket No. HS 102 DIV

First Inventor or Application Identifier Gary A. Bannon

Title METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY

Express Mail Label No. EL320554231US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		Assistant Commissioner for Patents U ADDRESS TO:  Box Patent Application Washington, DC 20231				
2.	repeter 600 concerning utility patent application contents.  Ree Transmittal Form (e.g., PTO/SB/17)  Submit an original and a duplicate for fee processing)  Recification [Total Pages]  Recification	Mashington, DC 20231  5. Microfiche Computer Program (Appendix) 6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies  ACCOMPANYING APPLICATION PARTS 7. Assignment Papers (cover sheet & document(s)) 8. X 37 C.F.R.§3.73(b) Statement (when there is an assignee) 9. English Translation Document (if applicable) 10. X Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations 11. X Preliminary Amendment 12. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
b. Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed)  i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).  **NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:  Continuation  To prior application information:  Examiner  Nolan, P.  Group / Art Unit:  13. **Small Entity Statement filed in prior application, Status still proper and desired (if foreign priority is claimed)  Other:  Check for \$407.00  **Other: Check for \$407.00  The requisite information below and in a preliminary amendment: of prior application No: 09 , 141,220  Group / Art Unit: 1644  For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied  Under Box 4b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by						
reference. Th	the incorporation can only be relied upon when a portion 17. CORRESPOND	has been inadvertently omitted from the submitted application parts.				
Customer Number or Bar Code Label  (Insert Customer No. or Attach bar code label here)						
Name	Patrea L. Pabst, Esq. Arnall Golden & Gregory, LLP					
Address	2800 One Atlantic Center  1201 West Peachtree Street					
City	Atlanta State	GA Zip Code 30309-3450				
Country	United States Telephone	(404)873-8794 Fax (404)873-9795				
Name (F	Print Type) Patrea L. Pabst	Registration No. (Attomey/Agent) 31,284  Date 6 2006				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

+

PTO/SB/17 (12-98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**HS 102 DIV** 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No.

## FEE TRANSMITTAL Complete if Known Divisional of 09/141,220 **Application Number** for FY 1999 January 6, 2000 Filing Date Gary A. Bannon Patent fees are subject to annual revision. First Named Inventor Small Entity payments must be supported by a small entity statement, **Examiner Name** otherwise large entity fees must be paid. See Forms PTO/SB/09-12. Group / Art Unit

TOTAL AMOUNT OF PAYMENT (\$) 372.00

METHOD OF PAYMENT (check one)		FE	EE CALCULATION (continued)		
1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:		IONAL FE Small Entity Fee Fee Code (\$)		Fee Paid	
Account 01-2507	105 130	205 65	Surcharge - late filing fee or oath		
Deposit Account Name  Arnall Golden & Gregory, LLP	127 50	227 25	Surcharge - late provisional filing fee or cover sheet.		
Charge Any Additional	139 130	139 130	Non-English specification		
Fee Required Under 37 CFR 1.16 and 1.17	147 2,520	147 2,520	For filing a request for reexamination		
	112 920 <b>*</b>	112 920°	Requesting publication of SIR prior to Examiner action		
2. X Payment Enclosed: X Check Order Other	113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action		
	115 110	215 55	Extension for reply within first month	ļi	
FEE CALCULATION	116 380	216 190	Extension for reply within second month		
1. BASIC FILING FEE Large Entity Small Entity	117 870	217 435	Extension for reply within third month		
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	118 1,360	218 680	Extension for reply within fourth month		
101 760 201 380 Utility filing fee 345.00	128 1,850	228 925	Extension for reply within fifth month	<b></b>	
106 310 206 155 Design filing fee	119 300	219 150	Notice of Appeal		
107 480 207 240 Plant filing fee	120 300	220 150	Filing a brief in support of an appeal		
108 760 208 380 Reissue filing fee	121 260	221 130	Request for oral hearing  Petition to institute a public use proceeding	<del></del>	
114 150 214 75 Provisional filing fee	138 1,510	138 1,510	Petition to revive - unavoidable		
SUBTOTAL (1) (\$)345.00	140 110	240 55	Petition to revive - unintentional		
	141 1,210	241 605	Utility issue fee (or reissue)	<u> </u>	
2. EXTRA CLAIM FEES Fee from	142 1,210	242 605 243 215	Design issue fee		
Extra Claims below Fee Paid  Total Claims 23 -20 = 3 x 9.00 = 27.00	143 430 144 580	243 213	Plant issue fee	i	
Independent	122 130	122 130	Petitions to the Commissioner	<b></b>	
Nultiple Dependent	123 50	123 50	Petitions related to provisional applications	<b></b>	
indiaple Dependent	126 240	126 240		ļ i	
Large Entity Small Entity			Submission of Information Disclosure Stmt		
Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 146 760	581 40 246 380	Recording each patent assignment per property (times number of properties)		
103 18 203 9 Claims in excess of 20	146 760	L+0 300	Filing a submission after final rejection (37 CFR 1.129(a))		
102 78 202 39 Independent claims in excess of 3	149 760	249 380	For each additional invention to be		
104 260 204 130 Multiple dependent claim, if not paid			examined (37 CFR 1.129(b))	<u>  </u>	
109 78 209 39 ** Reissue independent claims over original patent	Other fee (sp	ecify)			
110 18 210 9 ** Reissue claims in excess of 20	**Represents the difference between the fee for a month				
and over original patent	extension of	of time and a	month extension of time.	<del></del>	
SUBTOTAL (2) (\$) 27.00	* Reduced by	Basic Filing F	Fee Paid SUBTOTAL (3) (\$)		
SUBMITTED BY			Complete (if applica	able)	
Typed or Printed Name Patrea L. Pabst	)		Reg. Number 31,	284	
Signature		Date	Deposit Account User ID 01-	2507	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gary A. Bannon, A: Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin

Serial No.:

Divisional of U.S.S.N. 09/141,220

Express Mail Label

No.: EL320554231US

Date of Deposit: January 6, 2000

Filed:

January 6, 2000

For:

METHODS AND REAGENTS FOR DECREASING CLINICAL

REACTION TO ALLERGY

**Box Patent Application Assistant Commissioner for Patents** Washington, D.C. 20231

## REQUEST FOR FILING A DIVISIONAL APPLICATION UNDER 37 C.F.R. § 1.53(b)

Sir:

Pursuant to 35 U.S.C. § 21(a), as amended by Public Law 97-247, and 37 C.F.R. §§ 1.10 and 1.53(b), Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin enclose for filing the attached new divisional patent application entitled "Methods and Reagents for Decreasing Clinical Reaction to Allergy". The application includes a copy of prior application U.S.S.N. 09/141,220, including 1 page of abstract, 29 pages of specification, and 5 pages of claims. This application is a divisional of pending prior application Serial No. 09/141,220, filed August 27, 1998, entitled "Methods and Reagents for Decreasing Clinical Reaction to Allergy", by Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin.

Divisional of U.S.S.N. 09/141,220
"Methods and Reagents for Decreasing Clinical Reaction to Allergy"
By: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin REQUEST FOR FILING A DIVISIONAL
APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL320554231US Date of Deposit: January 6, 2000

Pursuant to 37.C.F.R. § 1.63(d), the copy of the executed Declaration included in the new application is a copy of the executed Substitute Declaration filed September 2, 1999, in parent application Serial No. 09/141,220, to which the new application claims benefit.

Please preliminarily amend the application in accordance with the enclosed Preliminary

Amendment. An Information Disclosure Statement is also enclosed.

Enclosed from prior application U.S.S.N. 09/141,220 are three sheets of formal drawings; copies of (1) Statement Claiming Small Entity Status by assignee University of Arkansas; (2) Statement Under 37 C.F.R. § 3.73(b) by assignee University of Arkansas; (3) Assignment from A. Wesley Burks, Jr. and Gary A. Bannon to University of Arkansas, recorded at Reel 010065, Frame 0008; (4) Statement Claiming Small Entity Status by assignee Mt. Sinai School of Medicine of the City University of New York; (5) Statement Under 37 C.F.R. § 3.73(b) by assignee Mt. Sinai School of Medicine of the City University of New York; (6) Assignment from Hugh A. Sampson to Mt. Sinai School of Medicine of the City University of New York, recorded at Reel 009539, Frame 0550; (7) Statement Claiming Small Entity Status by assignee Panacea Pharmaceuticals, LLC; (8) Statement Under 37 C.F.R. § 3.73(b) by assignee Panacea Pharmaceuticals, LLC.; and (9) Assignment from Howard Sosin to Panacea Pharmaceuticals, Inc., recorded at Reel 010190, Frame 0516.

A check in the amount of \$407.00 to cover the \$345.00 filing fee for a small entity and the \$27.00 fee for three claims in excess of twenty total claims is enclosed. The Commissioner is authorized to credit Deposit Account No. 01-2507 in the amount of \$35.00, which represents

Divisional of U.S.S.N. 09/141,220
"Methods and Reagents for Decreasing Clinical Reaction to Allergy"
By: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin REQUEST FOR FILING A DIVISIONAL
APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL320554231US Date of Deposit: January 6, 2000

the difference between the small entity filing fee effective prior to December 29, 1999, and the current fee. It is believed that this is the proper filing fee since the application includes 3 independent claims and a total of 23 claims after entry of the Preliminary Amendment. This application is entitled to small entity status as copies of the executed Statements Claiming Small Entity Status by each of the three assignees filed in prior application 09/141,220 are enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

The power of attorney in the prior application is to Patrea L. Pabst.

The inventorship for the claims in the new application is the same as in parent application Serial No. 09/141,220.

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R. § 1.821-1.825. The sequence listing for the new application is identical to the sequence listing for application Serial No. 09/141,220, filed August 27, 1998, by Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin. Sequence listings in computer readable form were submitted in Application Serial No. 09/141/220 on August 27, 1998, and again on December 10, 1999 in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Accordingly, pursuant to 37 C.F.R. § 1.821(e), applicants hereby request that the computer readable form of the sequence listing submitted in application Serial No. 09/141/220 on

Divisional of U.S.S.N. 09/141,220
"Methods and Reagents for Decreasing Clinical Reaction to Allergy"
By: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin REQUEST FOR FILING A DIVISIONAL
APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL320554231US Date of Deposit: January 6, 2000

December 10, 1999, be used as the computer readable form of the sequence listing for the new application. The application has a paper copy of the Sequence Listing incorporated therein.

I declare that the material in the prior sequence listing is identical to the paper copy of the Sequence Listing present in the new application, that the Sequence Listing does not add new matter to the application, and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements may jeopardize the validity of the application or any patent issuing thereon.

This application is being filed on January 6, 2000, by mailing the application to the Assistant Commissioner of Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label Number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3450

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the

Divisional of U.S.S.N. 09/141,220

"Methods and Reagents for Decreasing Clinical Reaction to Allergy"

By: Gary A. Bannon, A. Wesley Burks, Jr., Hugh A. Sampson, and Howard B. Sosin REQUEST FOR FILING A DIVISIONAL

APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL320554231US

Date of Deposit: January 6, 2000

United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: January 6, 2000

ARNALL, GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax)